Skip to content
Resources > Reports

Navigating Biopharma Policy: 2025 Changes and a Look Ahead

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael
IndustryLife Sciences & Healthcare

Biopharma firms are grappling with a turbulent and complex policy landscape. The threat of 100% tariffs on imported branded drugs have fundamentally altered business strategy for firms, spurring dealmaking with the federal government in exchange for tariff relief. Heightened policy uncertainty is forcing manufacturers to reevaluate pricing and go-to-market strategies, with a severe expected revenue impact.

AlphaSense recently hosted a webinar with Dr. Robert Popovian, Chief Science Policy Officer at the Global Health Living Foundation to discuss these issues and more. This report leverages key insights from Dr. Popovian and those available in AlphaSense to explore the key policy shifts shaping the biopharma ecosystem.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

Luxury at an Inflection Point: What the Numbers Aren’t Telling Investors

Luxury has enjoyed close to four decades of near-continuous growth, and the industry has come to view that run as a baseline rather than an exception.
ReportConsumer/CPGFinancial Services
Dark blue graphic with the title "Luxury at an Inflection Point: What the Numbers Aren't Telling Investors." Features blue line drawings of a watch, handbag, and high heels, with text mentioning interviews with LVMH and Prada executives.

Key Debates Transforming Healthcare and Life Sciences in 2026

2026 is a year of transition for healthcare and life sciences as the industry moves toward more convenient, patient-centric care.
ReportLife Sciences & HealthcareFinancial Services
A graphic titled "Key Debates Transforming Healthcare and Life Sciences in 2026", featuring stylized illustrations of a medicine bottle, a pill, a microscope, and a DNA helix on a blue background.

Key Debates Transforming Technology, Media, and Telecom in 2026

In this report, we harness broker research, Tegus Expert Insights, and company commentary in AlphaSense to explore how the debates below are shaping the technology, media, and telecom landscape in 2026.
Report
Blue line art illustration with the title "Key Debates Transforming Technology, Media, and Telecom in 2026," featuring a CPU, server rack, and an airplane.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.